Quick Facts

• Primary Use: Treatment intended to help manage Type 1 Diabetes Mellitus.
• Secondary Use: Treatment intended to help manage Type 2 Diabetes Mellitus.
• Therapeutic Goal: Works to contribute to the overall control of blood glucose (sugar) levels.

---

NovoMix 50 is a therapeutic option indicated for the treatment of diabetes mellitus in adults. This medication is used when a patient requires insulin to help stabilize and control blood glucose levels throughout the day.

It is specifically employed to help manage both Type 1 and Type 2 diabetes. In the context of Type 2 diabetes, this preparation may be used alone or in combination with other oral diabetes medications to help achieve desired glycemic control. This medication is associated with improved overall blood glucose control compared to certain conventional human insulins.

Appropriate dosage and administration should be determined by a healthcare professional based on individual metabolic needs and regular blood glucose monitoring.

NovoMix 50 (biphasic insulin aspart) is approved for use only in adults (18 years of age and older). Its safety and effectiveness have not been established in the paediatric population (children and adolescents under 18), and therefore its use is not recommended in this age group.

Contraindications and Restrictions

NovoMix 50 is contraindicated (must not be used) in the following circumstances:

• During episodes of hypoglycemia (low blood sugar).
• In patients with a known hypersensitivity or allergy to insulin aspart or any of the product's excipients.

It is also not recommended for the treatment of diabetic ketoacidosis. The medicine must be administered only by subcutaneous injection; it must not be given intravenously or used in insulin infusion pumps.

Special Populations

Use in elderly patients (age 65 or older) and individuals with hepatic or renal impairment (liver or kidney problems) is permitted. However, in these patient groups, regulatory documents require that glucose monitoring be intensified and the dose of insulin be adjusted on an individual basis, as insulin requirements may be reduced. For pregnant and breast-feeding individuals, treatment is generally considered permissible, though careful blood glucose control is recommended throughout pregnancy.

Interaction Map: Interactions with other medicines and products — official regulatory information for NovoMix 50

---

Interaction Scope

Classification	Categories with Documented Pharmacodynamic Interactions
Enhance Glucose-Lowering Effect	Oral antidiabetic products, ACE inhibitors, MAOIs, Salicylates, Anabolic steroids, Sulfonamides
Reduce Glucose-Lowering Effect	Oral contraceptives, Thiazides, Glucocorticoids, Thyroid hormones, Sympathomimetics, Growth hormone, Danazol, GLP-1 receptor agonists

Mechanistic basis of interactions (only if stated in label):

The interaction profile is primarily based on pharmacodynamic effects that result in either an additive or opposing influence on blood glucose levels. There are no documented pharmacokinetic interactions involving the cytochrome P450 (CYP) enzyme system or drug transporters.

Interaction-related constraints:

• Hypoglycemia Symptom Masking: Co-administration with Beta-blockers is officially documented to mask the physiological signs of hypoglycemia, such as tremor or palpitations.
• Alcohol Interaction: Alcohol may either potentiate or reduce the blood-glucose-lowering action, which affects glycemic control.

Timing and Population Notes:

• No mandatory timing or separation rules for co-administration are defined in the regulatory label.
• No specific population-dependent interaction considerations (e.g., heightened severity in renal or hepatic impairment) are detailed in the official interaction section.

---

Resulting Interaction Structure

The regulatory profile is defined by two major classifications: substances that officially enhance the glucose-lowering action and substances that officially reduce this action. This structure emphasizes the impact on glycemic balance as the central constraint of co-administration. The official documentation identifies agents that may result in hypoglycemia (additive effect) or hyperglycemia (opposing effect), while formal contraindicated medicinal product combinations are not listed.

NovoMix 50 is a biphasic suspension comprising 50% soluble insulin aspart and 50% intermediate-acting insulin aspart protamine crystals. The active substance is a modified human insulin, an agonist at the insulin receptor (IR), a heterotetrameric protein found on the cell membranes of target tissues, including skeletal muscle, adipose tissue, and hepatocytes.

Binding of insulin aspart to the alpha-subunit of the IR activates the intrinsic tyrosine kinase activity of the beta-subunit. This initiates autophosphorylation and subsequent phosphorylation of Insulin Receptor Substrates (IRS) proteins.

The activated IRS proteins mediate the molecular cascade, notably stimulating the Phosphatidylinositol 3-Kinase (PI3K) / Akt (Protein Kinase B) pathway. Within skeletal muscle and adipose tissue, this pathway promotes the translocation of Glucose Transporter type 4 (GLUT4) vesicles to the plasma membrane, facilitating increased glucose uptake from the systemic circulation.

Concurrently, insulin aspart inhibits the hepatic gluconeogenesis pathway and suppresses lipolysis and proteolysis. The combination of rapid-acting soluble insulin aspart and the slow-release protamine-crystallized form modulates systemic glucose kinetics, ensuring a biphasic physiological response characterized by a rapid post-administration activity followed by a prolonged, sustained effect.

Administration of NovoMix 50

NovoMix 50 is a suspension for injection that is typically administered subcutaneously. It is designed for injection into the abdominal wall, the thigh, the upper arm, or the gluteal region. The absorption of the insulin may vary depending on the specific injection site chosen.

Injection Technique

To ensure consistent absorption, it is common practice to rotate injection sites within the same anatomical region. The suspension must be resuspendend immediately before use. When properly resuspended, the liquid should appear uniformly white and cloudy.

Timing of Use

NovoMix 50 is a dual-acting insulin containing both rapid-acting and intermediate-acting components. Because of its rapid onset of action, it is generally administered immediately before a meal. When necessary, it may also be administered soon after a meal.

Storage and Handling

The product should be used according to the specific temperature and handling requirements to maintain its stability. It is intended for use with compatible delivery systems, such as insulin pens or syringes, depending on the specific presentation of the medication.

NovoMix 50: Recent Clinical Evidence

1. Evidence for Glycemic Control in Diabetes Mellitus (Type 1 and Type 2)

Research has examined NovoMix 50 in individuals with Diabetes Mellitus, covering both Type 1 and Type 2 presentations. This evidence primarily consists of Randomized Controlled Trials (RCTs) and Systematic Reviews, which help contextualize findings from clinical trials, along with observational data. Researchers monitored outcomes related to systemic or functional imbalance by examining long-term blood glucose markers (glycosylated hemoglobin, or HbA1c) and short-term glucose patterns, specifically fasting blood glucose levels and post-meal blood glucose levels (postprandial glucose). The trials chiefly included adult patients (age 18 and older). Findings describe patterns observed in the studies when comparing this formulation to conventional human premixed insulins, focusing on post-meal blood glucose measurements.

2. Comparative Research Against Other Treatments

Research has specifically examined NovoMix 50 in studies alongside its predecessor, biphasic human insulin 30 (a conventional human premix). Studies reported patterns when comparing this 50/50 formulation to the 30/70 human insulin formulation, specifically examining data related to overall blood glucose markers in the adult populations studied. In individuals with Type 2 Diabetes, research also examined the use of NovoMix 50 alongside certain other oral antidiabetic medications. These studies explored how combining the preparation with these other treatments was associated with different observed patterns of blood glucose measurements compared to the oral medications used alone.

3. Study Duration and Evidence Gaps

The main efficacy trials typically monitored changes in blood glucose measurements over time intervals ranging from 12 to 28 weeks. Longer-term, non-randomized observational studies have provided data that spans up to 12 months. However, long-term outcomes are not well characterized beyond the duration of these controlled research settings. A key limitation is that comparative evidence is lacking against all of the newer, alternative basal-bolus or lower-mix insulin analog regimens. Furthermore, the results apply only to the populations studied, meaning the applicability of the findings to pediatric or certain specific special populations may be uncertain. Research in these specific areas is ongoing.

Common questions about NovoMix 50 (FAQ)

---

Q: How quickly does the rapid-acting component of NovoMix 50 begin to work?

According to the official product information, the rapid-acting component of NovoMix 50 is expected to begin working relatively quickly. Its onset of action is reported to occur within 10 to 20 minutes after a subcutaneous injection. This characteristic helps the medication cover the rapid rise in glucose that occurs following a meal.

---

Q: What is the full duration of action of one dose of NovoMix 50?

Studies cited in regulatory documents indicate that the effect of one dose of NovoMix 50 has a prolonged duration. The overall duration of action is reported to last for up to 14 to 15 hours following the subcutaneous injection. This prolonged effect is due to the 50% intermediate-acting insulin component.

---

Q: Are there specific long-term risks associated with using insulin aspart products like NovoMix 50?

Official warnings exist concerning the risk of peripheral neuropathy (nerve pain) which can be associated with insulin use. Furthermore, regulatory documents contain specific warnings about the potential for heart failure in some patients when this medicine is used alongside certain oral diabetes medications known as Thiazolidinediones (TZDs).

---

Q: What are the signs of a severe allergic reaction to NovoMix 50?

A severe generalized hypersensitivity reaction (anaphylaxis) is a reported, life-threatening adverse event. Regulatory documents describe signs which may include widespread skin rash, itching, sweating, stomach or bowel disturbance, swelling of the throat, or difficulty breathing.

---

Q: Can common non-prescription pain relievers interact with NovoMix 50?

Official drug interaction information indicates that some common medications may affect how NovoMix 50 works. Medications containing salicylates (a class which includes some pain relievers) are specifically listed as agents that may potentiate, or strengthen, the glucose-lowering effect of the insulin.

---

Q: What is the difference between NovoMix 50 and NovoMix 30?

The difference primarily lies in the ratio of the insulin aspart components. NovoMix 50 provides a 50% rapid-acting and 50% intermediate-acting ratio. In contrast, the related formulation, NovoMix 30, contains a 30% rapid-acting and 70% intermediate-acting ratio.

---

Q: How does NovoMix 50 compare to a basal-bolus insulin regimen?

Official research evidence and clinical trials are generally lacking for direct comparisons against all of the newer, alternative basal-bolus or lower-mix insulin analog regimens. Comparative evidence has historically focused on conventional human biphasic insulin, and direct research against newer regimens is limited.

---

Q: Does NovoMix 50 contain zinc or other non-insulin ingredients?

Yes, the medicine contains several non-insulin components, also known as excipients. These include agents such as glycerol, phenol, metacresol, zinc chloride, and protamine sulfate. These components are included to maintain the stability and specific formulation of the product.

---

Q: What does the term "protamine" mean in relation to the insulin component of NovoMix 50?

The official composition description includes protamine sulfate. Protamine is a substance used to create the intermediate-acting component by forming crystals with the insulin aspart. This crystallization process is what causes that portion of the dose to be absorbed more slowly, providing a prolonged effect.

---

Q: Is it known if NovoMix 50 passes into breast milk?

According to regulatory documents, it is unknown if the active ingredient, insulin aspart, is excreted in human breast milk. The topic of insulin use during breastfeeding is addressed in regulatory documents.

---

Q: What is lipodystrophy, and is it a risk when injecting NovoMix 50?

Lipodystrophy is a change in the fat tissue that may cause the skin to either thin (atrophy) or thicken (hypertrophy) at the injection site. Official safety information lists this as a common side effect associated with the use of NovoMix 50. The importance of rotating injection sites is emphasized in the administration guidelines.

---

Q: What should I do if my regular warning signs of low blood sugar change after starting NovoMix 50?

Official product information warns that certain conditions or co-administered drugs can alter or mask the usual signs of low blood sugar (hypoglycemia). Conditions such as long-standing diabetes or the use of beta-blocker medicines are specifically noted as potentially affecting these warning symptoms.

---

Q: What are the key findings from research on NovoMix 50's effect on HbA1c levels?

Studies have examined the effect of NovoMix 50 on long-term blood glucose markers, such as HbA1c. Official research findings indicate that the medicine was associated with reductions in HbA1c that were considered non-inferior to the results observed with biphasic human insulin 30.

---

Q: Is it safe to use NovoMix 50 if I have a history of heart failure or swelling (edema)?

Regulatory documents include warnings regarding the use of NovoMix 50 alongside certain oral diabetes medicines (TZDs). This combination can potentially cause or worsen heart failure in some patients and may also lead to fluid retention (edema). Oedema is also listed as a common side effect of NovoMix 50 itself.

---

Q: Why must NovoMix 50 be administered shortly before or after a meal?

The medicine must be administered in immediate relation to a meal because of its specific composition. NovoMix 50 contains a rapid-acting insulin aspart component which is designed to act quickly to cover the expected rise in glucose that occurs immediately after eating.

---

Q: What are the main differences between NovoMix 50 and human biphasic insulin?

Research studies have compared the performance of NovoMix 50 (an insulin analog) to conventional human biphasic insulin. Evidence indicates that NovoMix 50 is generally associated with a faster onset of action. This faster action may lead to a lower post-meal glucose measurement compared to conventional human biphasic insulin.

---

Q: Are there special warnings for patients who have trouble recognizing low blood sugar?

Official regulatory warnings note that the usual symptoms of low blood sugar (hypoglycemia) may be less pronounced, altered, or absent in specific populations. This includes individuals with long-standing diabetes, autonomic neuropathy, or those taking certain drugs such as beta-blockers.

---

Q: Is the long-acting portion of NovoMix 50 considered a true basal insulin?

The intermediate-acting component of NovoMix 50 is classified as protamine-crystallized insulin aspart. While it is intended to provide a prolonged, sustained effect necessary for background, or basal, coverage, it is an intermediate-acting component rather than a single, full-duration basal insulin.

---

Q: What types of food or dietary changes might affect the action of NovoMix 50?

The regulatory interaction map specifically notes that consumption of alcohol may either potentiate (strengthen) or reduce the glucose-lowering action of the medicine. This impact on glycemic control is a key consideration when using NovoMix 50.

Storage and Disposal of NovoMix 50

The storage of NovoMix 50 (insulin aspart/insulin aspart protamine) is governed by specific regulatory conditions to maintain stability and potency.

---

Official Storage Requirements

Condition	Requirement
Unopened Storage	Store in a refrigerator between 2 C and 8 C; keep in the original outer carton to protect from light.
In-Use Storage	Store at room temperature, below mathbf30 C, for a maximum of 4 weeks (28 days). Do not refrigerate.
Mandatory Restriction	The product must not be frozen in any state. Any frozen product must be discarded.
Child Safety	Keep out of the sight and reach of children.

---

Disposal

Disposal must follow local regulatory requirements. Used needles and syringes should be placed immediately in a puncture-resistant sharps container. Unused or expired medication must not be thrown away via household trash or flushed down the sink/toilet.